IL149561A0 - Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue - Google Patents

Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue

Info

Publication number
IL149561A0
IL149561A0 IL14956100A IL14956100A IL149561A0 IL 149561 A0 IL149561 A0 IL 149561A0 IL 14956100 A IL14956100 A IL 14956100A IL 14956100 A IL14956100 A IL 14956100A IL 149561 A0 IL149561 A0 IL 149561A0
Authority
IL
Israel
Prior art keywords
nervous tissue
stimulate regeneration
substituted hypoxanthine
hypoxanthine derivatives
derivatives
Prior art date
Application number
IL14956100A
Other languages
English (en)
Original Assignee
Neotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotherapeutics Inc filed Critical Neotherapeutics Inc
Publication of IL149561A0 publication Critical patent/IL149561A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14956100A 1999-11-16 2000-10-27 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue IL149561A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/442,151 US6288069B1 (en) 1999-11-16 1999-11-16 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
PCT/US2000/041645 WO2001036419A1 (en) 1999-11-16 2000-10-27 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue

Publications (1)

Publication Number Publication Date
IL149561A0 true IL149561A0 (en) 2002-11-10

Family

ID=23755734

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14956100A IL149561A0 (en) 1999-11-16 2000-10-27 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue

Country Status (12)

Country Link
US (1) US6288069B1 (de)
EP (1) EP1230242A1 (de)
JP (1) JP2003517469A (de)
KR (1) KR20020050283A (de)
AU (1) AU3637901A (de)
BR (1) BR0015574A (de)
CA (1) CA2387809A1 (de)
EA (1) EA200200572A1 (de)
IL (1) IL149561A0 (de)
MX (1) MXPA02004935A (de)
NO (1) NO20022325D0 (de)
WO (1) WO2001036419A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091133A1 (en) * 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
US6906190B2 (en) * 2002-01-04 2005-06-14 Ribapharm Inc. Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
US7132103B2 (en) * 2003-08-01 2006-11-07 Enhan Technology Holdings International Co., Ltd. Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury
US20080039247A1 (en) * 2006-08-02 2008-02-14 Sandra L. Uhler Footbag And A System Relating Thereto
KR102156871B1 (ko) 2020-01-13 2020-09-24 주식회사 제이에스티 비산 저감이 가능한 집진장치를 이용한 하이브리드 폴리우레아 복합방수공법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321369A (en) 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3438486A (en) 1966-08-17 1969-04-15 David Pinkas Pick array
BE759011A (fr) 1969-11-17 1971-05-17 Wellcome Found Aminopurines
DE2554453A1 (de) 1974-12-18 1976-06-24 Experimentales Et Cliniques De Medikament zur glykaemieregulierung
US4221909A (en) 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4340726A (en) 1980-03-14 1982-07-20 Newport Pharmaceuticals International, Inc. Esters
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US4952693A (en) 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives
US5495010A (en) 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
EP0691348A1 (de) 1988-04-19 1996-01-10 Institut Pasteur Aus Adenylat-Cyclase von B. Parapertussis hergestellte immunogemische Zusammensetzungen
IT1227389B (it) 1988-07-07 1991-04-08 Mini Ricerca Scient Tecnolog Dispersioni acquose di polimeri uretano-acrilici e loro impiego come vernici.
US5256677A (en) 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5091432A (en) 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5801184A (en) 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5795756A (en) 1995-12-11 1998-08-18 Johnson; Roger A. Method and compounds for the inhibition of adenylyl cyclase
US5948771A (en) 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
AU3785799A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Method for treating migraine in mammals
AU3879899A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Novel dopamine-like 9-substituted hypoxanthine and methods of use
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use

Also Published As

Publication number Publication date
EA200200572A1 (ru) 2003-02-27
KR20020050283A (ko) 2002-06-26
CA2387809A1 (en) 2001-05-25
BR0015574A (pt) 2005-04-12
NO20022325L (no) 2002-05-15
NO20022325D0 (no) 2002-05-15
WO2001036419A9 (en) 2002-08-08
JP2003517469A (ja) 2003-05-27
WO2001036419A1 (en) 2001-05-25
AU3637901A (en) 2001-05-30
MXPA02004935A (es) 2005-09-08
US6288069B1 (en) 2001-09-11
EP1230242A1 (de) 2002-08-14

Similar Documents

Publication Publication Date Title
EG25204A (en) Benzo diazepine derivatives for the treatment of neurological disorders
ZA200603221B (en) Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
GB2371558B (en) Treatment of crude oils
GB2351911B (en) System to provide medical electrical stimulation to nervous tissue
AP2001002218A0 (en) The use of 4-h-1- benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
HK1090634A1 (en) Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
IL165397A0 (en) Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
IL149073A0 (en) Synthesis and methods of use of 9-substituted guanine derivatives
IL147748A0 (en) Use of etodolac to treat cancer
IL165216A0 (en) Methods of treating gastrointestinal and genitouririnary pain disorders using vinlafaxin and derivatives
HUP0201280A2 (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
IL160928A0 (en) Use of histamine to treat liver disease
PL352030A1 (en) Treatment to neurotic disorders
NO20021829D0 (no) Anvendelse av karbonmonoksydavhengige guanylylcyklase- modifisatorer for å stimulere neuritogenese
PL378210A1 (pl) Zastosowanie steroidów do leczenia osób cierpiących z powodu zaburzeń gałki ocznej
IL149561A0 (en) Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
HK1046089A1 (zh) 褪黑激素的治療用途
IL161231A0 (en) Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease
GB9926968D0 (en) Treatment of neurological disorders
EP1472282A4 (de) Verwendung von calmodulin zur förderung der knochenregeneration
IL145600A0 (en) Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins
HUP9902167A3 (en) Use of phenylnaphthalene derivatives to make medicaments for treating diseases of the central nervous system
EP1096948A4 (de) Verwendung von interleukin-11 zur behandlung gastrointestinaler krankheiten
AU2003253847A8 (en) Alkaloid derivatives and methods of their use